Norwegen - Norwegisch - Statens legemiddelverk

ge healthcare b.v. - strontium (89sr) klorid - injeksjonsvæske, oppløsning - 150 mbq

Norwegen - Norwegisch - Statens legemiddelverk

ge healthcare as - tetrofosmin - pulver til injeksjonsvæske, oppløsning

Norwegen - Norwegisch - Statens legemiddelverk

ge healthcare as - albumin humant kolloidale partikler ad tc-99m albumin nanokolloid - pulver til injeksjonsvæske, suspensjon

Norwegen - Norwegisch - Statens legemiddelverk

rotop pharmaka gmbh - mertiatid - preparasjonssett til radioaktive legemidler - 0.2 mg/2.5 ml

Norwegen - Norwegisch - Statens legemiddelverk

curium netherlands b.v. - albumin humant serum makroaggregater ad tc-99m makroalbumin - pulver til injeksjonsvæske, oppløsning

Norwegen - Norwegisch - Statens legemiddelverk

curium netherlands b.v. - talliumklorid (201tl) - injeksjonsvæske, oppløsning - 37 mbq/ ml

Norwegen - Norwegisch - Statens legemiddelverk

curium netherlands b.v. - dimerkaptosuccininsyre - preparasjonssett til radioaktive legemidler - 1.2 mg

Europäische Union - Norwegisch - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroksysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Europäische Union - Norwegisch - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabin - forløper t-celle lymfoblastisk leukemi-lymfom - antineoplastiske midler - nelarabine er indisert for behandling av pasienter med t-celle akutt lymfoblastisk leukemi (t-all) og t-celle lymfoblastisk lymfom (t-lbl) hvis sykdommen ikke har svart eller har tilbakefall etter behandling med minst to kjemoterapi regimer. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.

Europäische Union - Norwegisch - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influensavirusoverflateantigener (hemagglutinin og neuraminidase) av stamme a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaksiner - aktiv immunisering mot h5n1 subtype av influensa a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.